Nesta Therapeutics

Nesta Therapeutics is a pre-clinical stage biotechnology company focused on developing a novel class of tRNA-based medicines. The company's platform is designed to address genetic diseases caused by nonsense mutations, which result in premature stop codons and truncated, non-functional proteins. By engineering transfer RNAs (tRNAs) to recognize and read through these stop codons, Nesta aims to restore the production of full-length, functional proteins. The company is currently advancing its pipeline across multiple therapeutic areas where nonsense mutations are a primary driver of disease pathology. Backed by Atlas Venture, Nesta is positioned at the forefront of the emerging tRNA therapeutics landscape.